IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

VIGANO', MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.364
NA - Nord America 3.666
AS - Asia 1.822
SA - Sud America 92
AF - Africa 38
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 10
Totale 13.006
Salva come PNG Salva come JPEG
Nazione #
GB - Regno Unito 3.589
US - Stati Uniti d'America 3.578
CN - Cina 982
DE - Germania 907
IT - Italia 712
SE - Svezia 637
UA - Ucraina 338
FR - Francia 264
IN - India 219
TR - Turchia 199
IE - Irlanda 196
RU - Federazione Russa 185
KR - Corea 171
EU - Europa 130
FI - Finlandia 116
HK - Hong Kong 99
NL - Olanda 97
PL - Polonia 95
DK - Danimarca 82
CA - Canada 81
CO - Colombia 73
GR - Grecia 52
BE - Belgio 43
VN - Vietnam 37
ID - Indonesia 25
SG - Singapore 19
JP - Giappone 17
UZ - Uzbekistan 13
ES - Italia 12
TH - Thailandia 12
AU - Australia 11
RO - Romania 11
CH - Svizzera 10
SL - Sierra Leone 10
BR - Brasile 8
EG - Egitto 6
MY - Malesia 5
PT - Portogallo 5
AR - Argentina 4
BD - Bangladesh 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
GH - Ghana 4
IR - Iran 4
MX - Messico 4
PH - Filippine 4
RS - Serbia 4
AT - Austria 3
ET - Etiopia 3
NZ - Nuova Zelanda 3
CU - Cuba 2
KE - Kenya 2
MA - Marocco 2
MM - Myanmar 2
PE - Perù 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CL - Cile 1
EC - Ecuador 1
IL - Israele 1
IQ - Iraq 1
LB - Libano 1
LY - Libia 1
NG - Nigeria 1
PA - Panama 1
PS - Palestinian Territory 1
SC - Seychelles 1
SD - Sudan 1
SN - Senegal 1
UY - Uruguay 1
Totale 13.127
Salva come PNG Salva come JPEG
Città #
Southend 3.430
Chandler 619
Seattle 312
Jacksonville 298
Milan 262
Beijing 255
Princeton 232
Ashburn 231
Dublin 182
Frankfurt am Main 175
Wilmington 175
Ann Arbor 153
Nanjing 139
Mountain View 131
Dearborn 115
Redmond 115
Serra 90
Warsaw 90
Hong Kong 83
Andover 80
Fairfield 80
Boardman 79
Sakarya 79
Des Moines 76
Bengaluru 75
Toronto 72
Bogotá 71
Woodbridge 64
Somerville 56
Jinan 45
Hebei 44
Shenyang 44
Athens 39
Shanghai 38
Grafing 37
Brussels 36
Nanchang 35
Phoenix 33
Saint Petersburg 33
Houston 30
Tianjin 30
New York 27
Kiez 26
Redwood City 26
Berlin 23
Bitonto 23
Hangzhou 22
Helsinki 22
Guangzhou 21
Turin 21
Mumbai 19
Zhengzhou 19
Nürnberg 18
Changsha 17
Fremont 16
San Diego 16
Kunming 15
Munich 15
Hanoi 14
Menlo Park 14
Central District 13
Eitensheim 13
Los Angeles 13
Hefei 12
Jiaxing 12
Palaiseau 12
Rome 11
Roxbury 11
Scranton 11
Auburn Hills 10
Lanzhou 10
Levico Terme 10
Palermo 10
Pune 10
Washington 10
Cambridge 9
Dong Ket 9
Ningbo 9
Boise 8
Pskov 8
Verona 8
Chengdu 7
Hanover 7
San Sperate 7
Seoul 7
Ankara 6
Bangkok 6
Cagliari 6
Chicago 6
Costa Mesa 6
Gussago 6
London 6
Moscow 6
Odernheim 6
Ottawa 6
Sunnyvale 6
Bühl 5
Chongqing 5
Haikou 5
Hamburg 5
Totale 8.970
Salva come PNG Salva come JPEG
Nome #
Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice : the Italian multicenter experience 335
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 257
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice : high efficacy and favorable safety profile over 3 years of treatment 254
Combined lamivudine and adefovir dipivoxil treatment allows safe and long-term compath-1H therapy in refractory B-cell chronic lymphocytic leukemia with HBV reactivation 222
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 221
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients 205
Real life experiences in HCV management in 2018 205
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 197
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 190
Accuracy of two new predictive models in assessing fibrosis in chronic hepatitis C (CHC) 187
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 186
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 178
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H 174
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 172
US features of liver surface nodularity as a predictor of severe fibrosis in chronic hepatitis C 169
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 168
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 167
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 166
Inhibition of HBV-replication by combined treatment of lamivudine and adefovir dipivoxil allows long-term campath-1H therapy in refractory B-cell chronic lymphoblastic leukemia 166
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegykated interferon-α2A in chronic hepatitis C : an in vitro and in vivo study 164
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 164
Combination therapy with adefovir dipivoxil (ADV)and lamivudine (LAM) in LAM-resistant patients enlisted for liver transplantation 161
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 160
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 157
Clinical implications of HBsAg quantification in patients with chronic hepatitis B 155
Severe hepatic fibrosis in chronic hepatitis C 154
PegBeLiver study : HBsAg decline at week 24 of extended Peginterferon Alfa-2A (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype D patients 153
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 152
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 151
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 149
Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis 148
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 143
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 143
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 143
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 141
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-alpha 2a in chronic hepatitis C : an in vitro and in vivo study 140
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports 139
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants 138
Evaluating liver fibrosis in chronic hepatitis c (CHC), accuracy of two new predictive models 137
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 137
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 137
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 137
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 136
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 136
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 136
Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease 136
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 135
Ruolo delle crioglobuline sieriche nel corso dell'epatopatia cronica HCV-correlata. Studio prospettico di coorte di 343 pazienti 134
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 134
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 134
Lamivudine prophylaxis of hepatitis B reactivation in anti-HBC seroposivive patients undergoing chemotherapy for onco-hematological diseases 132
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 128
No evidence for ADV resistance in HBeAg negative lamivudine resisstant patients treated with lamivudine-adefovir combination for 3 years 127
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 127
No evidence for ADV resistance in HBeAg-negative Lamivudine resistant patients treated with LAMIVUDINE-ADEFOVIR combination for 3 years 124
Acute hepatitis following assumption of a herbal remedy 123
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 122
Changes in liver stiffness during entecavir therapy in patients with chronic hepatitis B 122
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 121
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 121
Entecavir for nuc-naïve chronic hepatitis b patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients 121
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma 121
Protocol liver biopsies to evaluate severity of recurrent HCV hepatitis : a recent monocentric experience 120
Failure of adefovir 20 mg to improve suboptimal response in lamivudine resistant hepatitis B patients treated with adefovir 10 mg and lamivudine 119
Transient elastography predicts response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B 118
Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation 117
Efficacy and safety of pegylated interferon plus ribavirin in patients with hepatitis C recurrence after liver transplantation : a single centre experience 115
Natural history and clinical impact of cryoglobulins in chronic hepatitis C : 10-year prospective study of 343 patients 113
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 112
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 112
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 112
Graft dysfunction (GD) in HBV recurrence free recipience is associated with serum autoantibodies reactivity 109
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients 107
A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C : a comparison using histology with internal-external validation 103
Erythroid differentiation is suppressed by ribavirin during combination therapy with pegylated interferon-α2a in chronic hepatitis C: an in vitro and in vivo study 103
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 102
Low risk of hepatocellular carcinoma recurrence after liver transplantation : a 3-year follow-up study in 78 patients with chronic hepatitis B 101
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 100
Late graft dysfunction (GD) in HBV recurrence-free recipients is associated with serum antinuclear antibodies (ANA) reactivity 99
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 99
Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination : A 4- year cohort study in 63 patients 95
Six years of "on demand" LAM plus ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 94
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 94
Safety and tolerability of extended (96 weeks) treatment with peginterferon alfa-2a [40kd] in genotype D patients with HBeAg-negative chronic hepatitis B 91
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal 90
Progressive decline of HBsAg titers in long-term virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 89
HBV and HCV Therapy 87
PegIFN-α2a for the treatment of chronic hepatitis B and C : a 10-year history 85
High rates of hepatitis B virus riverse seroconversion in anti-HBc carriers undergoing allogeneic bone marrow transplantation 83
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma 81
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection 79
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs) 79
AISF position paper on HCV in immunocompromised patients 77
Review article : The potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection 74
Low risk of hepatitis B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis : a retrospective multicenter Italian study 72
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy 71
Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? 70
Optimal therapy of chronic hepatitis B : how do I treat my HBeAg-negative patients? 68
Systematic review with meta-analysis : do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? 67
The prognosis and management of inactive HBV carriers 66
Totale 13.365
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.005
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.005
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019273 0 0 0 0 0 0 0 0 0 111 88 74
2019/20201.742 233 46 73 172 84 186 155 130 334 172 116 41
2020/20211.825 98 127 153 31 129 111 114 134 213 87 412 216
2021/20221.426 127 79 73 94 62 66 121 121 131 210 81 261
2022/20231.803 231 224 144 252 195 351 34 88 176 29 52 27
2023/2024912 29 82 39 55 331 118 76 90 38 54 0 0
Totale 13.904